Research Article

Sodium Valproate Inhibits the Growth of Human Cholangiocarcinoma In Vitro and In Vivo

Bing Wang, Rui Yang, Yue Wu, Hongbo Li, Zouxiao Hu, Yongjun Chen, and Shengquan Zou

Department of General Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China

Correspondence should be addressed to Shengquan Zou; sqzou05@aliyun.com

Received 1 June 2013; Accepted 27 August 2013

Academic Editor: Fabio Farinati

Copyright © 2013 Bing Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. None of treatment options for Cholangiocarcinoma (CCA), including surgery, adjuvant radiotherapy and chemotherapy, and ultimately liver transplantation, have been shown to substantially improve the survival rate in patients with CCA. Valproic acid (VPA), a histone deacetylase inhibitor, has been shown to display potent antitumor effects. In this study, sodium valproate, the clinically available form of VPA, was tested for its ability to inhibit the growth of cholangiocarcinoma cells, both in vitro and in vivo.

Materials and Methods. Cholangiocarcinoma cells (TFK-1, QBC939, and CCLP1) of different origins were treated with sodium valproate to determine their effects on cell proliferation and differentiation, cell cycle regulation, apoptosis, and autophagy. The in vivo effects of sodium valproate on cholangiocarcinoma growth were assessed using a xenograft mouse model injected with TFK-1 cells.

Results. Sodium valproate inhibited cholangiocarcinoma cell growth by inducing cell cycle arrest, cell differentiation, and apoptosis; sodium valproate effects were independent of autophagy. Tumor growth inhibition was also observed in vivo using TFK-1 xenografts.

Conclusion. The in vitro and in vivo outcomes provide preclinical rationale for clinical evaluation of sodium valproate, alone or in combination with other drugs, to improve patient outcome in cholangiocarcinoma.

1. Introduction

Cholangiocarcinoma (CCA) is a highly aggressive malignancy with features of biliary epithelial differentiation, which arises from the epithelia lining the intrahepatic or the extrahepatic bile ducts. Recent data from the USA and UK suggest that the worldwide incidence and mortality from CCA appears to be increasing over the past few decades [1]. The prognosis of CCA is poor because most tumors are advanced at the time of diagnosis. Although several improved therapeutic modalities have emerged and new-targeted therapies are being developed, surgery is the only curative treatment for patients with CCA. Unfortunately, less than one-third of tumors are resectable at diagnosis [2–4]. 5-year survival rates following resection of intrahepatic CCA, distal extrahepatic CCA, and hilar tumors are 22–44%, 27–37%, and 11–41%, respectively [2, 4]. Thus, novel therapeutic approaches need to be developed for the successful treatment of CCA.

Histone deacetylase (HDAC) inhibitors are a class of molecules that modify chromatin structure and regulate gene transcription and expression [5]. Valproic acid (VPA) (Figure 1), a HDAC inhibitor, exerts its primary action by targeting the enzyme HDAC [6, 7]. Sodium valproate is the clinically available form of VPA and is one of the most frequently prescribed antiepileptic drugs [8]. VPA is employed clinically in the treatment of schizophrenia, bipolar disorders, and different forms of headaches. It is also currently under experimental and clinical investigation as an anticancer drug [9]. VPA has shown potent antitumor effects in a variety of in vitro and in vivo systems, like glioma [10], breast [11], colon [12, 13], prostate [14, 15], and hepatoma [16, 17]. VPA modulates the behavior of various tumor cells by affecting multiple pathways including cell cycle arrest, apoptosis, angiogenesis, metastasis, differentiation, and senescence [18]. VPA is commonly evaluated, either alone or in combination with other agents, in the treatment of hematological malignancies [19]. There is, however, an increasing interest for VPA testing in solid tumors [20, 21], including phase I and phase II clinical studies. Currently,
Figure 1: Chemical structure of valproate (VPA, 2-propylpentanoic acid).

there have been few studies on the growth inhibitory effect of sodium valproate on CCA in vitro and in vivo. The objective of the present study was to demonstrate that sodium valproate inhibits CCA growth both in vitro and in vivo. Using TFK-1, QBC939, and CCLP1 cells, we evaluated the effects of sodium valproate on cell proliferation, cell differentiation, cell cycle arrest, apoptosis, and autophagy, which enable further insight into the possible mechanisms of sodium valproate. In vitro studies used an athymic nude mouse model bearing xenografts of TFK-1 cells, with sodium valproate at a concentration of 300 mg/kg [22], to determine whether sodium valproate inhibits the growth of CCA xenografts.

2. Material and Methods

2.1. Cell Culture and Reagents. The human cholangiocarcinoma cell lines, TFK-1 and CCLP1, were purchased from an official cell bank (DSMZ, Germany). QBC939 cells were kindly provided by Dr. Shuguang Wang (the Third Military Medical University, China). TFK-1 cells were originally obtained from a peripheral extrahepatic bile duct [23]. CCLP1 cells were obtained from a peripheral cholangiocarcinoma [24]. QBC939 cells were obtained from intrahepatic cholangiocarcinomas. TFK-1 [25] and QBC939 cells [26] were cultured and maintained in a humidified atmosphere containing 5% CO₂ at 37°C in RPMI 1640 (GIBCO, Life Technologies, Grand Island, NY), supplemented with 10% fetal bovine serum (GIBCO). CCLP1 [27] cells were cultured and maintained in a humidified atmosphere containing 5% CO₂ at 37°C in Dulbecco's Modified Eagle Medium (DMEM and GIBCO), supplemented with 10% fetal bovine serum (GIBCO), 2 mM L-glutamine, and 50 μg/mL gentamicin. Sodium valproate was obtained from Sigma-Aldrich (St. Louis, MO) and then dissolved in water to a final concentration of 20 mmol/L. Aliquots were stored at −20°C until use to avoid multiple freeze thaw cycles.

2.2. Measurement of Cell Growth and Viability. The growth of cholangiocarcinoma cell lines was determined using a Cell Counting Kit-8 (CCK-8) assay according to the instructions of the manufacturer (Dojindo, Japan). TFK-1 cells (1 × 10⁴), QBC939 cells (5 × 10⁵) and CCLP1 cells (5 × 10⁴) were plated in 6 replicates, cultured for 24 h in 96-well plates, and subsequently treated with sodium valproate at the indicated concentrations up to 120 h. Culture media containing the selected inhibitor was changed daily. After the incubation of the above cell lines with the indicated concentrations of sodium valproate, CCK-8 solution was added at a final concentration of 10 μL/100 μL medium and incubated for an additional 2 h at 37°C. The sample absorbance at 450 nm was determined using a scanning spectrophotometer (Thermo, USA).

2.3. Cell Cycle Analysis. Briefly, cells were grown for 24 h and treated with the indicated concentrations of sodium valproate for 24 h, 72 h, or 120 h. Cell cycle analysis was assessed by staining with propidium iodide (PI) and examined by flow cytometry (Becton Dickinson, Franklin Lakes, NJ).

2.4. Detection of Cell Differentiation. TFK-1 and QBC939 cells in the exponential phase were treated with 0, 0.5, and 2 mM sodium valproate. After 120 h of incubation, cell morphology was analyzed microscopically.

2.5. Measurement of Apoptosis Induction. TFK-1 cells were treated with sodium valproate (0–8 mM) for 120 h without changing the medium. Apoptosis was determined by a dual-color flow cytometric (FCM) procedure featuring fluorescence isothiocyanate (FITC)-Annexin-V and propidium iodide (PI) staining, according to an Apoptosis Detection Kit (KeyGen, China).

2.6. Hoechst 33342/PI Staining. TFK-1 cells were exposed to sodium valproate (2 mM) for 120 h. The morphology of the apoptotic cells was observed under a fluorescence microscope after being stained with Hoechst 33342/PI (KeyGen).

2.7. Detection of Autophagy with Green Fluorescence Protein-Tagged MAP-LC3. TFK-1 and QBC939 cells were treated with sodium valproate (2 mM) for 3 days. On day 3, the cells were transfected with a green fluorescence protein (GFP)-tagged MAP-LC3 (GFP-LC3) plasmid. After 24 h, the cells were fixed in 4% paraformaldehyde for 30 minutes and mounted for confocal microscopy (Carl Zeiss, Germany). GFP-LC3 expression was used as the characteristic parameter for autophagy. GFP fluorescence was observed via confocal microscopy.

2.8. Growth of Cholangiocarcinoma Xenografts in Nude Mice. Evaluation of sodium valproate-induced effects in vivo was conducted using xenografts of TFK-1 cells in 6-week-old male Balb-c nu/nu mice with a median weight of 14–16 g. All animal experiments were carried out according to protocols approved by the Experimental Animal Center of Huazhong University of Science and Technology. Ten mice were divided into two treatment groups. All mice had 2 × 10⁶ TFK-1 cells transplanted subcutaneously into the upper-right flank. Treatment was started two weeks after implantation, at which point the tumors were palpable. The mice were injected intraperitoneally with (1) vehicle (control group) or (2) sodium valproate (300 mg/kg BW) every day. Treatment was continued for 14 days. Tumor size was measured 3 times per week and tumor volume was calculated according to the formula: volume \( V = \pi/6 \times \text{length} \times \text{width}^2 \). The mice were evaluated daily for morbidity and mortality.

2.9. Statistical Analysis. All in vitro and in vivo experiments were repeated in triplicate. Wilcoxon-Mann-Whitney-Test
was performed to determine the level of significance for the \textit{in vitro} studies. For \textit{in vivo} studies, the statistical significance was analyzed using the long-rank test. All results were expressed as the mean ± SD. Significance was assumed at $P < 0.05$.

3. Results

3.1. Effects of Sodium Valproate on Growth of CCA Cells. The CCA cell lines TFK-1 (0–10 mM), QBC939 (0–20 mM), and CCLP1 (0–20 mM) were cultured up to 120 h with various concentrations of sodium valproate, and cell proliferation was assessed by CCK8. Sodium valproate inhibited the proliferation of all the three cell lines in a time- and dose-dependent manner ($P < 0.05$) (Figure 2). We have demonstrated that TFK-1 cells were more sensitive to sodium valproate than the other two cell lines. QBC939 cells showed almost identical proliferation characteristics compared to CCLP1 cells. In TFK-1 cells, treatment with 2 mM sodium valproate for 72 h resulted in >50% suppression of cell proliferation (Figure 2(a)), whereas in QBC939 cells and CCLP1 cells, a 50% suppression required exposure to 8 mM sodium valproate for 120 h (Figures 2(b) and 2(c)). Further experiments were restricted to TFK-1 and/or QBC939 as the representative cell lines.

3.2. Inductive Effect of Sodium Valproate on TFK-1 Cell Line Differentiation. The differentiation status of CCA cells
4. Inductive effect of sodium valproate on TFK-1 cell differentiation. Dendrite-like structure formation in TFK-1 cells treated for 120 h with (a) 0 mM (control), (b) 0.5 mM, and (c) 2 mM sodium valproate. With the increase of sodium valproate concentration, the dendrite-like structures became progressively longer. The morphology of cells was analyzed using a Nikon FX-35A camera (200x magnification). Each experiment was performed in triplicate.

3.3. Induction of Apoptosis in TFK-1 Cells by Sodium Valproate. To examine whether the antiproliferative effects of sodium valproate are due to the induction of apoptosis, TFK-1 cells were incubated with 0–8 mM for 120 h, then stained with Annexin-V and PI, and analyzed via flow cytometry. Sodium valproate showed a strong dose-dependent induction of apoptosis in TFK-1 cells (Figure 4). 0.5 mM sodium valproate induced an apoptosis rate of 23% and 8 mM induced apoptosis in 70% of TFK-1 cells (Figure 4).

The apoptotic morphological changes of TFK-1 cells were observed via fluorescence microscopy using Hoechst 33342/PI staining after exposure to 2 mM sodium valproate for 120 h. In contrast to the untreated group, there were higher percentages of bright blue cells (apoptosis) in the sodium valproate-treated group (Figure 5).

3.4. Cell Cycle Arrest by Sodium Valproate in Cell Cycle Distribution. To determine whether the antiproliferative effects of sodium valproate on CCA growth results from inhibition of cell cycle, cell cycle analyses were performed on TFK-1 cells and QBC939 cells after exposure to sodium valproate for 24, 72, and 120 h. As shown in Figure 6, TFK-1 cells were arrested in the G2/M phase in a dose-dependent manner after sodium valproate treatment for 24 h, 72 h, and 120 h (Figure 6(a)). With increasing concentration of sodium valproate, the percentage of cells in the G2/M phase increased from 7.78% to 71.7% at 24 h, 12% to 42.53% at 72 h, and 10.72% to 75.57% at 120 h. This concentration-dependent accumulation of cells in the G2/M phase was accompanied by a decrease in the number of cells in G0/G1 phase and S phase (Figure 6(a)). In contrast, QBC939 cells displayed an increase in the G0/G1 fraction of cells with the increase of sodium valproate concentration (Figure 6(b)). With an increasing concentration of sodium valproate, the percentage of G0/G1 cells increased from 71.42% to 74.04% at 24 h, 63.07% to 91.82% at 72 h, and 63.07% to 90.27% at 120 h. At the same time, the accumulation of QBC939 cells in the G0/G1 phase, there was a concomitant decrease in cells within S phase and a slight decrease in cells within the G2/M phase (Figure 6(b)).

3.5. Effect of Sodium Valproate on Autophagy. To assess whether there is a third possible mechanism that could contribute to the inhibitory effects of sodium valproate, we evaluated the role of autophagic cell death. TFK-1 cells and QBC939 cells were transiently transfected with a GFP-LC3 plasmid, treated with sodium valproate for 3 days, and then assessed for cell death via a confocal fluorescence microscope. The number of GFP-LC3 puncta counted in TFK-1 cells increased from 13 puncta per 100 cells (untreated control) to 21 puncta (2 mM treated TFK-1 cells) (Figures 7(a) and 7(b)), whereas in QBC939 cells, the number of puncta increased from 15 puncta per 100 cells (untreated control)
Figure 5: Apoptotic morphological changes in TFK-1 cells after treatment with sodium valproate. After 120 h, untreated control group (a) and 2 mM sodium valproate-treated TFK-1 cells (b) were loaded with Hoechst 33342/PI and then observed via fluorescence microscopy (100x magnification). Mixture of low blue with low pink fluorescence indicates live cells ((a), short arrow), while high blue fluorescence indicates apoptotic cells ((b), long arrow), and pink represents dead cells ((b), short arrow).

Figure 6: Effects of sodium valproate on cell cycle distribution in cholangiocarcinoma TFK-1 cells and QBC939 cells. (a) TFK-1 cells were incubated with 0–8 mM sodium valproate, and (b) QBC939 cells were incubated with 0–10 mM sodium valproate. On 24 h, 72 h, and 120 h, cells were harvested, and the fractions of cells in G0/G1-phase, S-phase, and G2/M-phase were determined by flow cytometry.

to 26 puncta (8 mM treated QBC939 cells) (Figures 7(c) and 7(d)). Considering these results, although VPA induced autophagic cell death to a certain degree, the autophagy cell rates remained at a low level.

3.6. Sodium Valproate Exhibits Inhibition of CCA Xenograft Growth. To further validate our in vitro studies, we utilized nude mice with subcutaneous human CCA xenografts. We evaluated the effect of sodium valproate treatment on tumor size and survival. As shown in Figure 8, animals treated with sodium valproate (300 mg/kg, injected intraperitoneally daily) showed statistically significant reduction in the tumor volume compared to the control group. Figure 9 shows the Kaplan-Meier survival curves for each experimental
Figure 7: Sodium Valproate induces autophagy in TFK-1 cells and QBC939 cells. TFK-1 cells and QBC939 cells were transfected with green fluorescence protein (GFP) and tagged with MAP-LC3 (GFP-LC3) plasmid and treated with sodium valproate at 2 mM and 8 mM, respectively. The formation of punctate GFP-LC3 spots is indicative of autophagy (short arrow).

group. Compared to control group, a statistically significant improvement in overall survival was observed in the sodium valproate group.

4. Discussion

Our previous work had reported that trichostatin A (TSA), an HDAC inhibitor, was effective at suppressing CCA cell growth [26]. Sodium valproate has been shown to have anticancer activity against a variety of tumor types. However, few studies have evaluated the antitumor activity of sodium valproate in CCA growth. In the present study, we found that sodium valproate inhibited the growth of CCA. CCK8 assays showed that CCA cells TFK-1, QBC939, and CCLP1 treated with sodium valproate led to reduced viability (Figure 1), especially with the extension of incubation time and increase in concentration.

Consistent with other solid tumors [28, 29], our data showed sodium valproate induces apoptosis in CCA cell lines. It was observed that TFK-1 cells appeared shrunken, with condensation of both nuclear chromatin and cytoplasm. The results of morphological changes were consistent with results from Annexin-V/PI staining. The finding sodium valproate induces apoptosis of CCA lines is also supported by studies in other gastrointestinal cancer lines. For example, VPA synergizes with TRAIL to induce apoptosis of the pancreatic cancer lines, MiaPaCa2, and Panc1 [30]. Also, the HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization in colon cancer cells [31].

Over the past ten years, there have been many studies on whether or not drugs inducing differentiation in vitro are effective in the treatment of patients with specific types of cancer. Differentiation was typically monitored by either morphological, enzymatic, or biochemical means [32]. Dendrite-like structure is a quantifiable marker of CCA cell differentiation. Our present studies demonstrated that sodium valproate induces TFK-1 cells to undergo terminal differentiation. More dendrite-like structures were observed with the extension of incubation time and the increase in sodium valproate concentration. Once the cells begin terminal differentiation, it is common that cell division and cell proliferation ceases. In a sense, sodium valproate can suppress the malignant phenotype of TFK-1 cells. Therefore, terminal differentiation of TFK-1 cells induced by sodium valproate should be important in inhibiting CCA cell proliferation in vitro. In line with our data, valproate affects differentiation and decreases proliferation of endometrial stromal sarcoma cells [33]. Also, in uveal melanoma cells, VPA induces cell growth arrest and differentiation [34].

One of the most common ways for inhibiting proliferation of tumor cells using antineoplastic agents is through their role in cell cycle arrest. Our present research provided experimental evidence that the antitumor effect of sodium valproate on TFK-1 and QBC939 cells is associated predominantly with cell cycle arrest. Other studies have reported that cells arrest at the G2/M phase after exposure to VPA [35, 36]. In line with this research, our experiments showed that the numbers of TFK-1 cells at the G2/M phase increased with the increase of sodium valproate concentration. Interestingly, QBC939 cells were arrested at the G0/G1 phase, but not at the G2/M phase. The reasons for this difference remain unclear and may warrant further mechanistic studies. However, in both cell lines, the dose-dependent decrease in S phase cells was observed with the increase of sodium valproate concentration.
To our knowledge, the induction of autophagy in CCA cells by sodium valproate has not been studied previously. In our study, although sodium valproate causes autophagy in CCA cells to a certain degree, the total autophagy rates remained at a relatively low level. Therefore, it can be concluded that autophagy may not be a primary mechanism by which sodium valproate induces cytotoxic effects in CCA cells.

A total of 300 mg/kg daily of sodium valproate over 2 weeks significantly reduced the growth of xenografted TFK-1 cells by 20.73%, which confirmed our in vitro data. However, a different VPA regimen may be required to treat other tumor types. Daily i.p. injections of 366 mg/kg VPA were necessary to inhibit gastrointestinal tumor growth in nu/nu mice [37], and neuroblastoma xenograft studies were based on 400 mg/kg VPA [38]. We also planned our animal experiments to evaluate the effect of sodium valproate treatment on survival of the animals and used the Kaplan-Meier method to calculate the mean percent survival time in both treatment and control groups. In our study, we discovered that the mice treated with sodium valproate suffer from comparatively lesser tumor burden and survive longer than the ones of the control groups.

In summary, the results from this study demonstrate that sodium valproate is capable of suppressing CCA cell growth both in vitro and in vivo and may provide a therapeutic benefit for treating CCA. However, there is still much to be studied regarding the molecular mechanism by which VPA induces differentiation, cell cycle arrest, and apoptosis. In addition, further studies of VPA in combination with classical chemotherapeutic drugs are necessary for a better understanding of CCA development/progression, which might lead to further clinical application of VPA in patients with liver diseases.

Acknowledgments

The investigation was supported by the Development of Novel Nano-Drug Delivery System Loaded with Traditional...
Chinese Anticancer medicine for the Targeted Therapy of Malignant Tumors which was issued by the Chinese Ministry of Science and Technology, Grant no. 2010DFA31870. The authors are very grateful to Professor Hagen von Briesen, Dr. Yvonne Kohl, and Dr. Sylvia Wagner for the helpful proof reading of the paper, and also thank Sonja Akiu for carefully reading the paper.

References

[1] S. A. Khan, S. Emadossadaty, N. G. Ladep et al., “Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?” Journal of Hepatology, vol. 56, no. 4, pp. 848–854, 2012.

[2] T. Sano, K. Shimada, Y. Sakamoto, J. Yamamoto, S. Yamasaki, and T. Kosuge, “One hundred two consecutive hepatobilary resections for perihilar cholangiocarcinoma with zero mortality,” Annals of Surgery, vol. 244, no. 2, pp. 240–247, 2006.

[3] B. Blechacz and G. J. Gores, “Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment,” Hepatology, vol. 48, no. 1, pp. 308–321, 2008.

[4] G. Nuzzo, F. Giuliani, F. Ardito et al., “Intrahepatic cholangiocarcinoma: prognostic factors after liver resection,” Updates in Surgery, vol. 62, no. 1, pp. 11–19, 2010.

[5] T. Jenuwein and C. D. Allis, “Translating the histone code,” Science, vol. 293, no. 5532, pp. 1074–1080, 2001.

[6] R. A. Blaheta and J. Cinatl Jr., “Anti-tumor mechanisms of valproate: a novel role for an old drug,” Medicinal Research Reviews, vol. 22, no. 5, pp. 492–511, 2002.

[7] C. J. Phiel, F. Zhang, E. Y. Huang, M. G. Guenther, M. A. Lazar, and P. S. Klein, “Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen,” Journal of Biological Chemistry, vol. 276, no. 39, pp. 36734–36741, 2001.

[8] E. Perucca, “Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience,” CNS Drugs, vol. 16, no. 10, pp. 695–714, 2002.

[9] R. H. Belmaker, “Bipolar disorder,” The New England Journal of Medicine, vol. 351, no. 5, pp. 476–518, 2004.

[10] C. M. Das, D. Aguiler, H. Vasquez et al., “Valproic acid induces p21 and topoisomerase-II (α/β) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines,” Journal of Neuro-Oncology, vol. 85, no. 2, pp. 159–170, 2007.

[11] N. P. Morgan and L. J. Gudas, “Valproic acid, in combination with all-trans retinoic acid and 5-aza-2’-deoxycytidine, restores expression of silenced RARβ2 in breast cancer cells,” Molecular Cancer Therapeutics, vol. 4, no. 3, pp. 477–486, 2005.

[12] X. Huang and B. Guo, “Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells,” Cancer Research, vol. 66, no. 18, pp. 9245–9251, 2006.

[13] J. S. Isenberg, Y. Jia, L. Field et al., “Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid,” British Journal of Pharmacology, vol. 151, no. 1, pp. 63–72, 2007.

[14] Q. Xia, J. Sung, W. Chowdhury et al., “Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo,” Cancer Research, vol. 66, no. 14, pp. 7237–7244, 2006.

[15] S. Shabbeer, M. S. Q. Kortenhorst, S. Kachhap, N. Galloway, R. Rodriguez, and M. A. Carducci, “Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo,” Prostate, vol. 67, no. 10, pp. 1099–1110, 2007.

[16] S. Armeanu, M. Bitzer, U. M. Lauer et al., “Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate,” Cancer Research, vol. 65, no. 14, pp. 6321–6329, 2005.

[17] A. Pathil, S. Armeanu, S. Venturelli et al., “HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL,” Hepatology, vol. 43, no. 3, pp. 425–434, 2006.

[18] A. Duenas-Gonzalez, M. Candelaria, C. Perez-Plascencia, E. Perez-Cardenas, E. de la Cruz-Hernandez, and L. A. Herrera, “Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors,” Cancer Treatment Reviews, vol. 34, no. 3, pp. 206–222, 2008.

[19] A. Kuendgen and N. Gattermann, “Valproic acid for the treatment of myeloid malignancies,” Cancer, vol. 110, no. 5, pp. 943–954, 2007.

[20] N. Carey and N. B. la Thangue, “Histone deacetylase inhibitors: gathering pace,” Current Opinion in Pharmacology, vol. 6, no. 4, pp. 369–375, 2006.

[21] D. C. Marchion, E. Bicaku, A. I. Daud, D. M. Sullivan, and P. N. Munster, “Valproic acid alters chromatin structure by regulation of chromatin modulation proteins,” Cancer Research, vol. 65, no. 9, pp. 3815–3822, 2005.

[22] P. Neri, P. Tagliaferri, M. T. di Martino et al., “In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor,” British Journal of Haematology, vol. 143, no. 4, pp. 520–531, 2008.

[23] S. Saijyo, T. Kudo, M. Suzuki et al., “Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1:” The Tohoku Journal of Experimental Medicine, vol. 177, no. 1, pp. 61–71, 1995.

[24] Y. Shimizu, A. J. Demetris, S. M. Gollin et al., “Two new human cholangiocarcinoma cell lines and their cytogenetics
and responses to growth factors, hormones, cytokines or immuno-logic effector cells,” *International Journal of Cancer*, vol. 52, no. 2, pp. 252–260, 1992.

[25] G. Fava, L. Marucci, S. Glaser et al., “γ-aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway,” *Cancer Research*, vol. 65, no. 24, pp. 11437–11446, 2005.

[26] L.-N. Xu, X. Wang, and S.-Q. Zou, “Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines,” *World Journal of Gastroenterology*, vol. 14, no. 16, pp. 2578–2581, 2008.

[27] K. Lim, C. Han, L. Xu, K. Isse, A. J. Demetris, and T. Wu, “Cyclooxygenase-2-derived prostaglandin E2 activates β-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by ω3 polyunsaturated fatty acids,” *Cancer Research*, vol. 68, no. 2, pp. 553–560, 2008.

[28] N. Takai, J. C. Desmond, T. Kumagai et al., “Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells,” *Clinical Cancer Research*, vol. 10, no. 3, pp. 1141–1149, 2004.

[29] C. M. Olsen, E. T. M. Meussen-Elholm, L. S. Røste, and E. Tauboll, “Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7,” *Molecular and Cellular Endocrinology*, vol. 213, no. 2, pp. 173–179, 2004.

[30] S. Schüler, P. Fritsche, S. Diersch et al., “HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells,” *Molecular Cancer*, vol. 9, article 80, 2010.

[31] X. Chen, P. Wong, E. Radany, and J. Y. C. Wong, “HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells,” *Cancer Biotherapy and Radiopharmaceuticals*, vol. 24, no. 6, pp. 689–699, 2009.

[32] R. E. Scott, “Differentiation, differentiation/gene therapy and cancer,” *Pharmacology and Therapeutics*, vol. 73, no. 1, pp. 51–65, 1997.

[33] A. Hrzenjak, F. Moinfar, M.-L. Kremser et al., “Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells,” *Molecular Cancer Therapeutics*, vol. 5, no. 9, pp. 2203–2210, 2006.

[34] S. Landreville, O. A. Agapova, K. A. Matatall et al., “Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma,” *Clinical Cancer Research*, vol. 18, no. 2, pp. 408–416, 2012.

[35] L. Qiu, A. Burgess, D. P. Fairlie, H. Leonard, P. G. Parsons, and B. G. Gabrielli, “Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells,” *Molecular Biology of the Cell*, vol. 11, no. 6, pp. 2069–2083, 2000.

[36] V. A. Florenes, M. Skrede, K. Jørgensen, and J. M. Nesland, “Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival,” *Melanoma Research*, vol. 14, no. 3, pp. 173–181, 2004.

[37] D. Y. Greenblatt, A. M. Vaccaro, R. Jaskula-Sztul et al., “Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells,” *Oncologist*, vol. 12, no. 8, pp. 942–951, 2007.

[38] Q. Yang, Y. Tian, S. Liu et al., “Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antangiogenesis strategy in neuroblastoma,” *Cancer Research*, vol. 67, no. 4, pp. 1716–1724, 2007.